ArticleBMC rheumatology2025
Add-on iguratimod or tacrolimus in methotrexate in patients with rheumatoid arthritis not achieving remission with methotrexate: a retrospective propensity score-matched study.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the efficacy and safety of combination therapy with iguratimod (IGU) versus tacrolimus (TAC) plus methotrexate (MTX) in patients with rheumatoid arthritis (RA) who failed to achieve remission with MTX monotherapy.
methodsThis retrospective, single-centre study included RA patients treated with IGU + MTX (n = 56) and TAC + MTX (n = 52). Propensity score matching generated two balanced cohorts (n = 30 per group). The primary endpoint was the Simplified Disease Activity Index (SDAI) remission rate at week 52. Secondary outcomes included disease activity parameters, drug retention rates, and safety profiles over 52 weeks.
resultsBoth regimens substantially improved disease activity from baseline. In the matched analysis, SDAI remission rates at week 52 were similar between IGU and TAC (43.3% vs. 46.7%, p = 1.00), as were drug retention rates (70.0% vs. 76.7%, p = 0.62). The TAC group showed numerically larger reductions in SDAI, Clinical Disease Activity Index, and C-reactive protein, though these differences were not statistically significant. Treatment discontinuations due to adverse events were infrequent, and both combinations were well tolerated.
conclusionsIn this retrospective study, combination therapy with IGU or TAC added to MTX was associated with favorable efficacy and safety in patients with RA not achieving remission with MTX monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.